EUVIMEDEUVIMED entdecken
Multizentrische Studie

Indication for biologics in a real-world cohort of dupilumab treated chronic rhinosinusitis with nasal polyps patients according to international recommendations: evidence from the European CRS Outcome Registry (CHRINOSOR)

G Mortuaire, S F Seys, J de Kinderen, G Bettio, C Cavaliere, S Reitsma, S Schneider, A Andrianakis, P-V Tomazic, M Wagenmann, A Ciofalo, Z Diamant und 11 weitere

Rhinology Journal · 2025

DOI: 10.4193/rhin25.157 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Rhinology Journal, 2025. Verfasst von G Mortuaire und 22 weiteren Autor:innen. Beteiligte Einrichtung: Otorhinolaryngology-Head and Neck Department, Huriez Hospital, Centre Hospitalier Universitaire (CHU) Lille, Lille, France. Hauptthemen laut MEDLINE: Sinusitis, Antibodies, Monoclonal, Humanized, Nasal Polyps, Rhinitis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Criteria for biologic treatment of uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) differ across international recommendations and prescription of biologics depends on national reimbursement criteria. CHRINOSOR offers an opportunity to analyse biologic indications in the real-world setting according to international recommendations.

Methods

CRSwNP patients who received dupilumab treatment in the ENT clinic of 6 tertiary centres (5 countries) were included. Baseline demographic and lifestyle factors, NP score, SinoNasal Outcome Test-22 score, visual analogue scale for sinus symptoms, and Asthma Control Test score were retrieved from the medical records. Indication criteria for biologic treatment according to EUFOREA 2021, and EPOS/EUFOREA 2023 recommendations was applied. Dupilumab effectiveness was assessed at baseline, 24 and 52 weeks in relation to these criteria.

Results

61.8% and 79.8% of patients met respectively the EUFOREA 2021 or the EPOS/EUFOREA 2023 indication criteria for biologic treatment. Dupilumab was effective in patients who met or did not meet international criteria for biologic indication. However, patients who met the indication criteria showed overall a more pronounced effect on most of the outcome parameters than patients who did not meet the criteria.

Conclusions

Real-world management of CRSwNP with biologics does not strictly follow the indication criteria established by international recommendations but depends on management criteria established by local authorities. These vary significantly and are either more or less stringent from one country to another. Dupilumab effectiveness in CRSwNP, whether these criteria are met or not, suggests that a broader CRSwNP population may benefit from dupilumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SinusitisAntibodies, Monoclonal, HumanizedNasal PolypsRhinitisBiological ProductsHumansChronic DiseaseMaleFemaleMiddle AgedRegistriesAdultEuropeTreatment OutcomeAgedRhinosinusitis

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedBiological Products

Autor:innen und Institutionen

  • Otorhinolaryngology-Head and Neck Department, Huriez Hospital, Centre Hospitalier Universitaire (CHU) Lille, Lille, France.
  • Galenus Health, Belgium.
  • Department of Sense Organs, Sapienza University, Rome, Italy.
  • Department of Otorhinolaryngology and head/neck surgery, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Otorhinolaryngology, Head and Neck Surgery, Vienna General Hospital (AKH), Medical University of Vienna, Vienna, Austria.
  • Department of General ORL, Head and Neck Surgery, Medical University of Graz, Graz, Austria.

Zitieren

APA

Mortuaire, G., Seys, S. F., de Kinderen, J., Bettio, G., Cavaliere, C., Reitsma, S., Schneider, S., Andrianakis, A., Tomazic, P. V., Wagenmann, M., Ciofalo, A., Diamant, Z., Eckl-Dorna, J., Fokkens, W. J., de Vincentiis, M., Holzmeister, C., Marin, G., Masieri, S., Otten, J. J., …, & I Alobid P W Hellings C Hopkins V Hox A Kjeldsen V J Lund A Laulajainen-Hongisto L Van Gerven, C. C. (2025). Indication for biologics in a real-world cohort of dupilumab treated chronic rhinosinusitis with nasal polyps patients according to international recommendations: evidence from the European CRS Outcome Registry (CHRINOSOR). Rhinology Journal. https://doi.org/10.4193/rhin25.157

Vancouver

Mortuaire G, Seys SF, de Kinderen J, Bettio G, Cavaliere C, Reitsma S, et al. Indication for biologics in a real-world cohort of dupilumab treated chronic rhinosinusitis with nasal polyps patients according to international recommendations: evidence from the European CRS Outcome Registry (CHRINOSOR). Rhinology Journal. 2025. doi:10.4193/rhin25.157

BibTeX
@article{Mortuaire2025,
  author = {Mortuaire, G and Seys, S F and de Kinderen, J and Bettio, G and Cavaliere, C and Reitsma, S and Schneider, S and Andrianakis, A and Tomazic, P-V and Wagenmann, M and Ciofalo, A and Diamant, Z and Eckl-Dorna, J and Fokkens, W J and de Vincentiis, M and Holzmeister, C and Marin, G and Masieri, S and Otten, J J and Scheckenbach, K and Tu, A and Bachert, C and I Alobid P W Hellings C Hopkins V Hox A Kjeldsen V J Lund A Laulajainen-Hongisto L Van Gerven, Chrinosor Consortium},
  title = {Indication for biologics in a real-world cohort of dupilumab treated chronic rhinosinusitis with nasal polyps patients according to international recommendations: evidence from the European CRS Outcome Registry (CHRINOSOR)},
  journal = {Rhinology Journal},
  year = {2025},
  doi = {10.4193/rhin25.157}
}
Kostenlos starten →